Heparin interference in anti-XA assays for rivaroxaban and apixaban

被引：0
|
作者：
Cutsforth, G. A. [1 ]
Finnegan, K. [2 ]
机构：
[1] Diagnostica Stago Inc, Vernon Hills, NJ USA
[2] SUNY Stony Brook, Stony Brook, NY 11794 USA
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO117-WED
引用
收藏
页码：795 / 795
页数：1
相关论文
共 50 条
  • [21] Rivaroxaban and Apixaban Anti-Xa Measurements: Impact of Plasma Storage for 7 Days at Room Temperature
    Boissier, Elodie
    Genebrier, Steve
    Lakhal, Karim
    Nedelec-Gac, Fabienne
    Trossaert, Marc
    Ternisien, Catherine
    Gouin-Thibault, Isabelle
    THROMBOSIS AND HAEMOSTASIS, 2018, 118 (08) : 1488 - 1490
  • [22] Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays
    Gouin-Thibault, Isabelle
    Flaujac, Claire
    Delavenne, Xavier
    Quenet, Sara
    Horellou, Marie-Helene
    Laporte, Silvy
    Siguret, Virginie
    Lecompte, Thomas
    THROMBOSIS AND HAEMOSTASIS, 2014, 111 (02) : 240 - 248
  • [23] Validation of rivaroxaban anti-Xa activity measurement
    Rathbun, S.
    Tafur, A. J.
    Mauer, K.
    Gausman, J.
    Marlar, R. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 964 - 965
  • [24] ANTI-XA ACTIVE HEPARIN OLIGOSACCHARIDES
    CHOAY, J
    LORMEAU, JC
    PETITOU, M
    SINAY, P
    CASU, B
    ORESTE, P
    TORRI, G
    GATTI, G
    THROMBOSIS RESEARCH, 1980, 18 (3-4) : 573 - 578
  • [25] THE CLINICAL IMPORTANCE OF HEPARIN ASSAYS IN PLASMA - CRITICAL ASPECTS IN ANTI-XA TECHNIQUES
    GIULIANI, R
    SZWARCER, E
    AQUINO, EM
    THROMBOSIS AND HAEMOSTASIS, 1981, 46 (01) : 376 - 376
  • [26] Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system
    Jakowenko, Nicholas
    Nguyen, Steffany
    Ruegger, Melanie
    Dinh, Ashley
    Salazar, Eric
    Donahue, Kevin R.
    THROMBOSIS RESEARCH, 2020, 196 : 276 - 282
  • [27] Evaluation of Anti-Xa Apixaban and Rivaroxaban Levels With Respect to Known Doses in Relation to Major Bleeding Events
    Nguyen, Steffany N.
    Ruegger, Melanie C.
    Salazar, Eric
    Dreucean, Diane
    Tatara, Alexandra W.
    Donahue, Kevin R.
    JOURNAL OF PHARMACY PRACTICE, 2022, 35 (06) : 836 - 845
  • [28] Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric Surgery
    Thom Kok
    Hans de Boer
    Bart Witteman
    Marcel Hovens
    Matthijs van Luin
    Houshang Monajemi
    Obesity Surgery, 2022, 32 : 607 - 614
  • [29] Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric Surgery
    Kok, Thom
    de Boer, Hans
    Witteman, Bart
    Hovens, Marcel
    van Luin, Matthijs
    Monajemi, Houshang
    OBESITY SURGERY, 2022, 32 (03) : 607 - 614
  • [30] Inclusion of a heparin neutralizer in the plasma diluent confers specificity to the FXa direct oral anticoagulants rivaroxaban, apixaban, and edoxaban in an anti-Xa chromogenic assay
    Goldford, M.
    Calhoon, W.
    Nguyen, D.
    Woodhams, B.
    Morris, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 : 15 - 15
12345